Coya receives $4.2M milestone from Dr. Reddy's for first ALS patient dosed

Coya Therapeutics, Inc.

Milestone triggered by first patient dosed in ALSTARS trial of COYA 302 for ALS.
Dosing announced Dec 9, 2025; payment received Dec 16, 2025.
Payment under Dec 2023 Development and License Agreement with Dr. Reddy's Labs.
COYA 302 is an investigational therapy targeting amyotrophic lateral sclerosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.